The Surveillance after Extremity Tumor Surgery (SAFETY) trial: Protocol for a pilot study to determine the feasibility of a multi-centre randomised controlled trial

The SAFETY Investigators

Research output: Contribution to journalArticle

Abstract

Introduction Following the treatment of patients with soft tissue sarcomas (STS) that are not metastatic at presentation, the high risk for local and systemic disease recurrence necessitates post-treatment surveillance. Systemic recurrence is most often detected in the lungs. The most appropriate surveillance frequency and modality remain unknown and, as such, clinical practice is highly varied. We plan to assess the feasibility of conducting a multi-centre randomised controlled trial (RCT) that will evaluate the effect on overall 5-year survival of two different surveillance frequencies and imaging modalities in patients with STS who undergo surgical excision with curative intent. Methods and analysis The Surveillance After Extremity Tumor Surgery trial will be a multi-centre 2×2 factorial RCT. Patients with non-metastatic primary Grade II or III STS treated with excision will be allocated to one of four treatment arms1: chest radiograph (CXR) every 3 months for 2 years2; CXR every 6 months for 2 years3; chest CT every 3 months for 2 years or4chest CT every 6 months for 2 years. The primary outcome of the pilot study is the feasibility of a definitive RCT based on a combination of feasibility endpoints. Secondary outcomes for the pilot study include the primary outcome of the definitive trial (overall survival), patient-reported outcomes on anxiety, satisfaction and quality of life, local recurrence-free survival, metastasis-free survival, treatment-related complications and net healthcare costs related to surveillance. Ethics and dissemination This trial received provisional ethics approval from the McMaster/Hamilton Health Sciences Research Ethics Board on 7 August 2019 (Project number 7562). Final ethics approval will be obtained prior to commencing patient recruitment. Once feasibility has been established and the definitive protocol is finalised, the study will transition to the definitive study. Trial registration NCT03944798; Pre-results.

Original languageEnglish (US)
Article numbere029054
JournalBMJ open
Volume9
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Clinical Protocols
Extremities
Randomized Controlled Trials
Ethics
Sarcoma
Survival
Recurrence
Neoplasms
Thorax
Outcome Assessment (Health Care)
Research Ethics
Therapeutics
Health Care Costs
Patient Selection
Anxiety
Quality of Life
Neoplasm Metastasis
Lung
Health

Keywords

  • pilot study
  • randomised controlled trial
  • soft tissue sarcoma
  • study protocol
  • surveillance

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The Surveillance after Extremity Tumor Surgery (SAFETY) trial : Protocol for a pilot study to determine the feasibility of a multi-centre randomised controlled trial. / The SAFETY Investigators.

In: BMJ open, Vol. 9, No. 9, e029054, 01.09.2019.

Research output: Contribution to journalArticle

@article{d40d8f775fd943dbbd6995fa74e32098,
title = "The Surveillance after Extremity Tumor Surgery (SAFETY) trial: Protocol for a pilot study to determine the feasibility of a multi-centre randomised controlled trial",
abstract = "Introduction Following the treatment of patients with soft tissue sarcomas (STS) that are not metastatic at presentation, the high risk for local and systemic disease recurrence necessitates post-treatment surveillance. Systemic recurrence is most often detected in the lungs. The most appropriate surveillance frequency and modality remain unknown and, as such, clinical practice is highly varied. We plan to assess the feasibility of conducting a multi-centre randomised controlled trial (RCT) that will evaluate the effect on overall 5-year survival of two different surveillance frequencies and imaging modalities in patients with STS who undergo surgical excision with curative intent. Methods and analysis The Surveillance After Extremity Tumor Surgery trial will be a multi-centre 2×2 factorial RCT. Patients with non-metastatic primary Grade II or III STS treated with excision will be allocated to one of four treatment arms1: chest radiograph (CXR) every 3 months for 2 years2; CXR every 6 months for 2 years3; chest CT every 3 months for 2 years or4chest CT every 6 months for 2 years. The primary outcome of the pilot study is the feasibility of a definitive RCT based on a combination of feasibility endpoints. Secondary outcomes for the pilot study include the primary outcome of the definitive trial (overall survival), patient-reported outcomes on anxiety, satisfaction and quality of life, local recurrence-free survival, metastasis-free survival, treatment-related complications and net healthcare costs related to surveillance. Ethics and dissemination This trial received provisional ethics approval from the McMaster/Hamilton Health Sciences Research Ethics Board on 7 August 2019 (Project number 7562). Final ethics approval will be obtained prior to commencing patient recruitment. Once feasibility has been established and the definitive protocol is finalised, the study will transition to the definitive study. Trial registration NCT03944798; Pre-results.",
keywords = "pilot study, randomised controlled trial, soft tissue sarcoma, study protocol, surveillance",
author = "{The SAFETY Investigators} and Michelle Ghert and Mohit Bhandari and Anthony Bozzo and Dijkstra, {P. D.Sander} and Anthony Griffin and Robert Grimer and James Hayden and Arlene Manherz and Karim Masrouha and Paula McKay and Benjamin Miller and Naveen Parasu and Ajay Puri and Randall, {R. Lor} and Patricia Schneider and Sheila Sprague and Nina Szpakowski and Lehana Thabane and Robert Turcotte and Roberto V{\'e}lez and David Wilson and Kevin Zbuk and Gordon Guyatt",
year = "2019",
month = "9",
day = "1",
doi = "10.1136/bmjopen-2019-029054",
language = "English (US)",
volume = "9",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - The Surveillance after Extremity Tumor Surgery (SAFETY) trial

T2 - Protocol for a pilot study to determine the feasibility of a multi-centre randomised controlled trial

AU - The SAFETY Investigators

AU - Ghert, Michelle

AU - Bhandari, Mohit

AU - Bozzo, Anthony

AU - Dijkstra, P. D.Sander

AU - Griffin, Anthony

AU - Grimer, Robert

AU - Hayden, James

AU - Manherz, Arlene

AU - Masrouha, Karim

AU - McKay, Paula

AU - Miller, Benjamin

AU - Parasu, Naveen

AU - Puri, Ajay

AU - Randall, R. Lor

AU - Schneider, Patricia

AU - Sprague, Sheila

AU - Szpakowski, Nina

AU - Thabane, Lehana

AU - Turcotte, Robert

AU - Vélez, Roberto

AU - Wilson, David

AU - Zbuk, Kevin

AU - Guyatt, Gordon

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Introduction Following the treatment of patients with soft tissue sarcomas (STS) that are not metastatic at presentation, the high risk for local and systemic disease recurrence necessitates post-treatment surveillance. Systemic recurrence is most often detected in the lungs. The most appropriate surveillance frequency and modality remain unknown and, as such, clinical practice is highly varied. We plan to assess the feasibility of conducting a multi-centre randomised controlled trial (RCT) that will evaluate the effect on overall 5-year survival of two different surveillance frequencies and imaging modalities in patients with STS who undergo surgical excision with curative intent. Methods and analysis The Surveillance After Extremity Tumor Surgery trial will be a multi-centre 2×2 factorial RCT. Patients with non-metastatic primary Grade II or III STS treated with excision will be allocated to one of four treatment arms1: chest radiograph (CXR) every 3 months for 2 years2; CXR every 6 months for 2 years3; chest CT every 3 months for 2 years or4chest CT every 6 months for 2 years. The primary outcome of the pilot study is the feasibility of a definitive RCT based on a combination of feasibility endpoints. Secondary outcomes for the pilot study include the primary outcome of the definitive trial (overall survival), patient-reported outcomes on anxiety, satisfaction and quality of life, local recurrence-free survival, metastasis-free survival, treatment-related complications and net healthcare costs related to surveillance. Ethics and dissemination This trial received provisional ethics approval from the McMaster/Hamilton Health Sciences Research Ethics Board on 7 August 2019 (Project number 7562). Final ethics approval will be obtained prior to commencing patient recruitment. Once feasibility has been established and the definitive protocol is finalised, the study will transition to the definitive study. Trial registration NCT03944798; Pre-results.

AB - Introduction Following the treatment of patients with soft tissue sarcomas (STS) that are not metastatic at presentation, the high risk for local and systemic disease recurrence necessitates post-treatment surveillance. Systemic recurrence is most often detected in the lungs. The most appropriate surveillance frequency and modality remain unknown and, as such, clinical practice is highly varied. We plan to assess the feasibility of conducting a multi-centre randomised controlled trial (RCT) that will evaluate the effect on overall 5-year survival of two different surveillance frequencies and imaging modalities in patients with STS who undergo surgical excision with curative intent. Methods and analysis The Surveillance After Extremity Tumor Surgery trial will be a multi-centre 2×2 factorial RCT. Patients with non-metastatic primary Grade II or III STS treated with excision will be allocated to one of four treatment arms1: chest radiograph (CXR) every 3 months for 2 years2; CXR every 6 months for 2 years3; chest CT every 3 months for 2 years or4chest CT every 6 months for 2 years. The primary outcome of the pilot study is the feasibility of a definitive RCT based on a combination of feasibility endpoints. Secondary outcomes for the pilot study include the primary outcome of the definitive trial (overall survival), patient-reported outcomes on anxiety, satisfaction and quality of life, local recurrence-free survival, metastasis-free survival, treatment-related complications and net healthcare costs related to surveillance. Ethics and dissemination This trial received provisional ethics approval from the McMaster/Hamilton Health Sciences Research Ethics Board on 7 August 2019 (Project number 7562). Final ethics approval will be obtained prior to commencing patient recruitment. Once feasibility has been established and the definitive protocol is finalised, the study will transition to the definitive study. Trial registration NCT03944798; Pre-results.

KW - pilot study

KW - randomised controlled trial

KW - soft tissue sarcoma

KW - study protocol

KW - surveillance

UR - http://www.scopus.com/inward/record.url?scp=85072391873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072391873&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2019-029054

DO - 10.1136/bmjopen-2019-029054

M3 - Article

C2 - 31537562

AN - SCOPUS:85072391873

VL - 9

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 9

M1 - e029054

ER -